Clinical Scorecard: Comparison of Buprenorphine-Naloxone and Extended-Release Naltrexone After Opioid Withdrawal Management

At a Glance

Key Highlights

• Buprenorphine-naloxone and XR naltrexone are effective in managing opioid use disorder.
• Observational studies suggest lower overdose rates with buprenorphine-naloxone compared to XR naltrexone.
• The study utilized a target trial emulation framework to compare treatment outcomes.

Guideline-Based Recommendations

Diagnosis

• Diagnosis of opioid use disorder based on clinical criteria.

Management

• Initiation of buprenorphine-naloxone or XR naltrexone within 28 days of MMOW discharge.

Monitoring & Follow-up

• Monitor for all-cause mortality and nonfatal opioid overdose within 24 weeks of discharge.

Risks

• Increased overdose risk has been observed in XR naltrexone group compared to buprenorphine-naloxone.

Patient & Prescribing Data

Individuals with opioid use disorder discharged from medically managed withdrawal programs.

Treatment strategies include buprenorphine-naloxone and XR naltrexone, with considerations for patient history and eligibility.

Clinical Best Practices

• Utilize a target trial emulation framework for observational studies.
• Ensure comprehensive eligibility criteria to minimize bias in treatment comparisons.
• Incorporate race and ethnicity data to adjust for structural factors affecting treatment outcomes.

Related Resources & Content

• Study on MOUD effectiveness